The global neovascular age-related macular degeneration treatment market is expected to garner a market value of US$ 3 billion in 2023 and is expected to accumulate a market value of US$ 4.89 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for neovascular age-related macular degeneration treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Neovascular Age-related Macular Degeneration Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. Neovascular age-related macular degeneration is a serious eye condition that affects older adults and can lead to vision loss. The treatment of nAMD typically involves medications that are injected into the eye to stop the growth of abnormal blood vessels in the retina. These medications are known as anti-VEGF drugs.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3 billion |
| Anticipated Forecast Value (2033) | US$ 4.89 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Neovascular Age-related Macular Degeneration Treatment reflected a value of 3.5% during the historical period, 2018 to 2022.
The neovascular age-related macular degeneration treatment market has been growing rapidly in recent years due to the increasing prevalence of nAMD and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.
The key players in the neovascular age-related macular degeneration treatment market include pharmaceutical companies such as Roche, Novartis, Regeneron, and Bayer. These companies are investing heavily in research and development to bring new and improved drugs to market for the treatment of nAMD. In addition to anti-VEGF drugs, other treatments for nAMD are also being developed, including gene therapy and sustained-release drug delivery systems. These new treatments have the potential to improve patient outcomes and reduce the need for frequent injections.
Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Neovascular Age-related Macular Degeneration Treatment market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones. The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. Overall, the market for neovascular age-related macular degeneration treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Growing Awareness along with increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth
The neovascular age-related macular degeneration (nAMD) treatment market has been experiencing significant growth in recent years and is expected to continue growing in the coming years. Several factors are driving this growth, including:
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of nAMD treatment with anti-VEGF drugs can be very high, and this can limit patient access to these treatments. Some patients may not be able to afford the cost of treatment, while others may face limitations in their insurance coverage.
Moreover, Anti-VEGF drugs are typically administered through injections directly into the eye, which can be uncomfortable and inconvenient for patients. Additionally, these injections need to be given on a regular basis, which can be challenging for patients who have difficulty traveling to clinics or for those who may be homebound.
Increasing awareness and diagnosis of the condition Shaping Landscape in South & East Asia
The neovascular age-related macular degeneration (nAMD) treatment market is turning out to be promising in the South & East Asia region. The prevalence of nAMD is increasing in the region due to aging populations, changing lifestyles, and increasing prevalence of diabetes.
Several pharmaceutical companies have been focusing on expanding their market presence in the region by investing in research and development, strategic partnerships, and collaborations. For example, Novartis and Roche have been leading players in the nAMD treatment market in the region, and have been expanding their product portfolios and conducting clinical trials for new treatments.
In addition, the availability of biosimilars of anti-VEGF drugs has increased in the region, which has made treatment more affordable for patients. The use of biosimilars has also increased competition in the market, leading to more affordable treatment options. However, challenges remain in the region, including limited access to specialized ophthalmologists, inadequate healthcare infrastructure in some areas, and low awareness of nAMD and its treatment options among patients and healthcare providers.
Overall, the nAMD treatment market in South & East Asia is expected to continue growing in the coming years, driven by factors such as increasing patient awareness, expanding healthcare infrastructure, and the introduction of new treatments.
Increasing Focus on technological advancements driving demand for Neovascular Age-related Macular Degeneration Treatment in North America
The aging population in North America is contributing to the increasing prevalence of nAMD. According to the American Academy of Ophthalmology, more than 10 million Americans are affected by AMD, with nAMD accounting for a significant portion of these cases.
North America is at the forefront of research and development of new nAMD treatments, and the availability of advanced treatment options such as anti-VEGF drugs has contributed to the growth of the market. Additionally, the introduction of gene therapy and sustained-release drug delivery systems has further expanded treatment options.
The strong healthcare infrastructure in North America has contributed to the growth of the nAMD treatment market, with access to specialized ophthalmologists, well-equipped healthcare facilities, and advanced diagnostic and treatment technologies. The increasing awareness of nAMD and its treatment options among patients and healthcare providers has contributed to the growth of the market. Patients are now seeking earlier diagnosis and treatment, which has increased the demand for effective nAMD treatments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Wet AMD segment to hold a significant share and push market growth
Wet AMD is likely to account for a significant share in the Neovascular Age-related Macular Degeneration Treatment market is Wet AMD. Wet AMD is a more severe form of the disease and can progress rapidly, causing severe vision loss or blindness if left untreated.
This has led to a higher demand for treatments that can effectively manage the condition, such as anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are used to block the growth of abnormal blood vessels and reduce fluid leakage in the retina, slowing down the progression of the disease and improving vision.
Late-stage AMD segment to hold a significant share and push market growth
Among the different stages of AMD, the Late-stage AMD segment is likely to account for a significant share in the neovascular age-related macular degeneration treatment market.
Late-stage AMD includes both wet AMD and geographic atrophy, which are advanced forms of the disease that can cause severe vision loss or blindness if left untreated. As a result, there is a higher demand for effective treatments for late-stage AMD, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, which can help slow down the progression of the disease and improve vision.
Key players in the market include companies such as Competition Deep Dive, Competition Deep Dive, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc., ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc.GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals Inc. along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3 billion |
| Market Value in 2033 | US$ 4.89 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The neovascular age-related macular degeneration treatment market size reaches US$ 3 billion in 2023.
The market is set to surge at a 5% CAGR, reaching a valuation of US$ 4.89 billion by 2033.
The market witnessed a 3.5% CAGR between 2018 and 2022.
The United States exhibits promising potential for neovascular age-related macular degeneration treatment due to its advanced healthcare infrastructure.
The Wet AMD segment demonstrates significant expansion in the neovascular age-related macular degeneration treatment market.
1. Executive Summary | Neovascular Age-related Macular Degeneration Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Ranibizumab
5.3.2. Aflibercept
5.3.3. Bevacizumab
5.3.4. Brolucizumab
5.3.5. Faricimab
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
6.3.1. Dry AMD
6.3.2. Wet AMD
6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033
7.3.1. Less Than 60
7.3.2. Between 60 to 80
7.3.3. More Than 80
7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033
8.3.1. Male
8.3.2. Female
8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Stage of Disease, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage of Disease, 2023 to 2033
9.3.1. Early-stage AMD
9.3.2. Intermediate AMD
9.3.3. Late-stage AMD
9.4. Y-o-Y Growth Trend Analysis By Stage of Disease, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By Stage of Disease, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
10.3.1. Hospital Pharmacy
10.3.2. Specialty Pharmacy
10.3.3. Online Pharmacy
10.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
10.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction
11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. MEA
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. United States
12.2.1.2. Canada
12.2.2. By Drug Type
12.2.3. By Disease Type
12.2.4. By Age Group
12.2.5. By Gender
12.2.6. By Stage of Disease
12.2.7. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Disease Type
12.3.4. By Age Group
12.3.5. By Gender
12.3.6. By Stage of Disease
12.3.7. By Distribution Channel
12.4. Key Takeaways
13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Brazil
13.2.1.2. Mexico
13.2.1.3. Rest of Latin America
13.2.2. By Drug Type
13.2.3. By Disease Type
13.2.4. By Age Group
13.2.5. By Gender
13.2.6. By Stage of Disease
13.2.7. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Disease Type
13.3.4. By Age Group
13.3.5. By Gender
13.3.6. By Stage of Disease
13.3.7. By Distribution Channel
13.4. Key Takeaways
14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Germany
14.2.1.2. United Kingdom
14.2.1.3. France
14.2.1.4. Spain
14.2.1.5. Italy
14.2.1.6. Rest of Europe
14.2.2. By Drug Type
14.2.3. By Disease Type
14.2.4. By Age Group
14.2.5. By Gender
14.2.6. By Stage of Disease
14.2.7. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Disease Type
14.3.4. By Age Group
14.3.5. By Gender
14.3.6. By Stage of Disease
14.3.7. By Distribution Channel
14.4. Key Takeaways
15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. India
15.2.1.2. Malaysia
15.2.1.3. Singapore
15.2.1.4. Thailand
15.2.1.5. Rest of South Asia
15.2.2. By Drug Type
15.2.3. By Disease Type
15.2.4. By Age Group
15.2.5. By Gender
15.2.6. By Stage of Disease
15.2.7. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Disease Type
15.3.4. By Age Group
15.3.5. By Gender
15.3.6. By Stage of Disease
15.3.7. By Distribution Channel
15.4. Key Takeaways
16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. China
16.2.1.2. Japan
16.2.1.3. South Korea
16.2.2. By Drug Type
16.2.3. By Disease Type
16.2.4. By Age Group
16.2.5. By Gender
16.2.6. By Stage of Disease
16.2.7. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Type
16.3.3. By Disease Type
16.3.4. By Age Group
16.3.5. By Gender
16.3.6. By Stage of Disease
16.3.7. By Distribution Channel
16.4. Key Takeaways
17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. Australia
17.2.1.2. New Zealand
17.2.2. By Drug Type
17.2.3. By Disease Type
17.2.4. By Age Group
17.2.5. By Gender
17.2.6. By Stage of Disease
17.2.7. By Distribution Channel
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Drug Type
17.3.3. By Disease Type
17.3.4. By Age Group
17.3.5. By Gender
17.3.6. By Stage of Disease
17.3.7. By Distribution Channel
17.4. Key Takeaways
18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
18.2.1. By Country
18.2.1.1. GCC Countries
18.2.1.2. South Africa
18.2.1.3. Israel
18.2.1.4. Rest of MEA
18.2.2. By Drug Type
18.2.3. By Disease Type
18.2.4. By Age Group
18.2.5. By Gender
18.2.6. By Stage of Disease
18.2.7. By Distribution Channel
18.3. Market Attractiveness Analysis
18.3.1. By Country
18.3.2. By Drug Type
18.3.3. By Disease Type
18.3.4. By Age Group
18.3.5. By Gender
18.3.6. By Stage of Disease
18.3.7. By Distribution Channel
18.4. Key Takeaways
19. Key Countries Market Analysis
19.1. U.S.
19.1.1. Pricing Analysis
19.1.2. Market Share Analysis, 2022
19.1.2.1. By Drug Type
19.1.2.2. By Disease Type
19.1.2.3. By Age Group
19.1.2.4. By Gender
19.1.2.5. By Stage of Disease
19.1.2.6. By Distribution Channel
19.2. Canada
19.2.1. Pricing Analysis
19.2.2. Market Share Analysis, 2022
19.2.2.1. By Drug Type
19.2.2.2. By Disease Type
19.2.2.3. By Age Group
19.2.2.4. By Gender
19.2.2.5. By Stage of Disease
19.2.2.6. By Distribution Channel
19.3. Brazil
19.3.1. Pricing Analysis
19.3.2. Market Share Analysis, 2022
19.3.2.1. By Drug Type
19.3.2.2. By Disease Type
19.3.2.3. By Age Group
19.3.2.4. By Gender
19.3.2.5. By Stage of Disease
19.3.2.6. By Distribution Channel
19.4. Mexico
19.4.1. Pricing Analysis
19.4.2. Market Share Analysis, 2022
19.4.2.1. By Drug Type
19.4.2.2. By Disease Type
19.4.2.3. By Age Group
19.4.2.4. By Gender
19.4.2.5. By Stage of Disease
19.4.2.6. By Distribution Channel
19.5. Germany
19.5.1. Pricing Analysis
19.5.2. Market Share Analysis, 2022
19.5.2.1. By Drug Type
19.5.2.2. By Disease Type
19.5.2.3. By Age Group
19.5.2.4. By Gender
19.5.2.5. By Stage of Disease
19.5.2.6. By Distribution Channel
19.6. U.K.
19.6.1. Pricing Analysis
19.6.2. Market Share Analysis, 2022
19.6.2.1. By Drug Type
19.6.2.2. By Disease Type
19.6.2.3. By Age Group
19.6.2.4. By Gender
19.6.2.5. By Stage of Disease
19.6.2.6. By Distribution Channel
19.7. France
19.7.1. Pricing Analysis
19.7.2. Market Share Analysis, 2022
19.7.2.1. By Drug Type
19.7.2.2. By Disease Type
19.7.2.3. By Age Group
19.7.2.4. By Gender
19.7.2.5. By Stage of Disease
19.7.2.6. By Distribution Channel
19.8. Spain
19.8.1. Pricing Analysis
19.8.2. Market Share Analysis, 2022
19.8.2.1. By Drug Type
19.8.2.2. By Disease Type
19.8.2.3. By Age Group
19.8.2.4. By Gender
19.8.2.5. By Stage of Disease
19.8.2.6. By Distribution Channel
19.9. Italy
19.9.1. Pricing Analysis
19.9.2. Market Share Analysis, 2022
19.9.2.1. By Drug Type
19.9.2.2. By Disease Type
19.9.2.3. By Age Group
19.9.2.4. By Gender
19.9.2.5. By Stage of Disease
19.9.2.6. By Distribution Channel
19.10. India
19.10.1. Pricing Analysis
19.10.2. Market Share Analysis, 2022
19.10.2.1. By Drug Type
19.10.2.2. By Disease Type
19.10.2.3. By Age Group
19.10.2.4. By Gender
19.10.2.5. By Stage of Disease
19.10.2.6. By Distribution Channel
19.11. Malaysia
19.11.1. Pricing Analysis
19.11.2. Market Share Analysis, 2022
19.11.2.1. By Drug Type
19.11.2.2. By Disease Type
19.11.2.3. By Age Group
19.11.2.4. By Gender
19.11.2.5. By Stage of Disease
19.11.2.6. By Distribution Channel
19.12. Singapore
19.12.1. Pricing Analysis
19.12.2. Market Share Analysis, 2022
19.12.2.1. By Drug Type
19.12.2.2. By Disease Type
19.12.2.3. By Age Group
19.12.2.4. By Gender
19.12.2.5. By Stage of Disease
19.12.2.6. By Distribution Channel
19.13. Thailand
19.13.1. Pricing Analysis
19.13.2. Market Share Analysis, 2022
19.13.2.1. By Drug Type
19.13.2.2. By Disease Type
19.13.2.3. By Age Group
19.13.2.4. By Gender
19.13.2.5. By Stage of Disease
19.13.2.6. By Distribution Channel
19.14. China
19.14.1. Pricing Analysis
19.14.2. Market Share Analysis, 2022
19.14.2.1. By Drug Type
19.14.2.2. By Disease Type
19.14.2.3. By Age Group
19.14.2.4. By Gender
19.14.2.5. By Stage of Disease
19.14.2.6. By Distribution Channel
19.15. Japan
19.15.1. Pricing Analysis
19.15.2. Market Share Analysis, 2022
19.15.2.1. By Drug Type
19.15.2.2. By Disease Type
19.15.2.3. By Age Group
19.15.2.4. By Gender
19.15.2.5. By Stage of Disease
19.15.2.6. By Distribution Channel
19.16. South Korea
19.16.1. Pricing Analysis
19.16.2. Market Share Analysis, 2022
19.16.2.1. By Drug Type
19.16.2.2. By Disease Type
19.16.2.3. By Age Group
19.16.2.4. By Gender
19.16.2.5. By Stage of Disease
19.16.2.6. By Distribution Channel
19.17. Australia
19.17.1. Pricing Analysis
19.17.2. Market Share Analysis, 2022
19.17.2.1. By Drug Type
19.17.2.2. By Disease Type
19.17.2.3. By Age Group
19.17.2.4. By Gender
19.17.2.5. By Stage of Disease
19.17.2.6. By Distribution Channel
19.18. New Zealand
19.18.1. Pricing Analysis
19.18.2. Market Share Analysis, 2022
19.18.2.1. By Drug Type
19.18.2.2. By Disease Type
19.18.2.3. By Age Group
19.18.2.4. By Gender
19.18.2.5. By Stage of Disease
19.18.2.6. By Distribution Channel
19.19. GCC Countries
19.19.1. Pricing Analysis
19.19.2. Market Share Analysis, 2022
19.19.2.1. By Drug Type
19.19.2.2. By Disease Type
19.19.2.3. By Age Group
19.19.2.4. By Gender
19.19.2.5. By Stage of Disease
19.19.2.6. By Distribution Channel
19.20. South Africa
19.20.1. Pricing Analysis
19.20.2. Market Share Analysis, 2022
19.20.2.1. By Drug Type
19.20.2.2. By Disease Type
19.20.2.3. By Age Group
19.20.2.4. By Gender
19.20.2.5. By Stage of Disease
19.20.2.6. By Distribution Channel
19.21. Israel
19.21.1. Pricing Analysis
19.21.2. Market Share Analysis, 2022
19.21.2.1. By Drug Type
19.21.2.2. By Disease Type
19.21.2.3. By Age Group
19.21.2.4. By Gender
19.21.2.5. By Stage of Disease
19.21.2.6. By Distribution Channel
20. Market Structure Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Market Share Analysis of Top Players
20.3.1. By Regional
20.3.2. By Drug Type
20.3.3. By Disease Type
20.3.4. By Age Group
20.3.5. By Gender
20.3.6. By Stage of Disease
20.3.7. By Distribution Channel
21. Competition Analysis
21.1. Competition Deep Dive
21.1.1. F.Hoffmann-La Roche AG
21.1.1.1. Overview
21.1.1.2. Product Portfolio
21.1.1.3. Profitability by Market Segments
21.1.1.4. Sales Footprint
21.1.1.5. Strategy Overview
21.1.1.5.1. Marketing Strategy
21.1.2. Bausch + Lomb
21.1.2.1. Overview
21.1.2.2. Product Portfolio
21.1.2.3. Profitability by Market Segments
21.1.2.4. Sales Footprint
21.1.2.5. Strategy Overview
21.1.2.5.1. Marketing Strategy
21.1.3. Novartis AG
21.1.3.1. Overview
21.1.3.2. Product Portfolio
21.1.3.3. Profitability by Market Segments
21.1.3.4. Sales Footprint
21.1.3.5. Strategy Overview
21.1.3.5.1. Marketing Strategy
21.1.4. Pfizer Inc.
21.1.4.1. Overview
21.1.4.2. Product Portfolio
21.1.4.3. Profitability by Market Segments
21.1.4.4. Sales Footprint
21.1.4.5. Strategy Overview
21.1.4.5.1. Marketing Strategy
21.1.5. Allergan Plc.
21.1.5.1. Overview
21.1.5.2. Product Portfolio
21.1.5.3. Profitability by Market Segments
21.1.5.4. Sales Footprint
21.1.5.5. Strategy Overview
21.1.5.5.1. Marketing Strategy
21.1.6. Acucela Inc.
21.1.6.1. Overview
21.1.6.2. Product Portfolio
21.1.6.3. Profitability by Market Segments
21.1.6.4. Sales Footprint
21.1.6.5. Strategy Overview
21.1.6.5.1. Marketing Strategy
21.1.7. Santen Pharmaceuticals Co.
21.1.7.1. Overview
21.1.7.2. Product Portfolio
21.1.7.3. Profitability by Market Segments
21.1.7.4. Sales Footprint
21.1.7.5. Strategy Overview
21.1.7.5.1. Marketing Strategy
21.1.8. Ophthotech Corporation
21.1.8.1. Overview
21.1.8.2. Product Portfolio
21.1.8.3. Profitability by Market Segments
21.1.8.4. Sales Footprint
21.1.8.5. Strategy Overview
21.1.8.5.1. Marketing Strategy
21.1.9. Alimera Sciences Inc.
21.1.9.1. Overview
21.1.9.2. Product Portfolio
21.1.9.3. Profitability by Market Segments
21.1.9.4. Sales Footprint
21.1.9.5. Strategy Overview
21.1.9.5.1. Marketing Strategy
21.1.10. GSK plc.
21.1.10.1. Overview
21.1.10.2. Product Portfolio
21.1.10.3. Profitability by Market Segments
21.1.10.4. Sales Footprint
21.1.10.5. Strategy Overview
21.1.10.5.1. Marketing Strategy
21.1.11. Regeneron Pharmaceuticals Inc.
21.1.11.1. Overview
21.1.11.2. Product Portfolio
21.1.11.3. Profitability by Market Segments
21.1.11.4. Sales Footprint
21.1.11.5. Strategy Overview
21.1.11.5.1. Marketing Strategy
21.1.12. Bayer AG
21.1.12.1. Overview
21.1.12.2. Product Portfolio
21.1.12.3. Profitability by Market Segments
21.1.12.4. Sales Footprint
21.1.12.5. Strategy Overview
21.1.12.5.1. Marketing Strategy
21.1.13. RXi Pharmaceuticals Inc.
21.1.13.1. Overview
21.1.13.2. Product Portfolio
21.1.13.3. Profitability by Market Segments
21.1.13.4. Sales Footprint
21.1.13.5. Strategy Overview
21.1.13.5.1. Marketing Strategy
22. Assumptions & Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Neovascular Age-related Macular Degeneration Treatment Market
